Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 4,213 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 4,213 shares of the business’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $29.98, for a total value of $126,305.74. Following the completion of the transaction, the chief financial officer now directly owns 128,365 shares of the company’s stock, valued at approximately $3,848,382.70. The trade was a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total value of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total transaction of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98.
• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.96, for a total value of $196,965.28.

Hims & Hers Health Trading Down 6.8 %

Hims & Hers Health stock opened at $26.56 on Friday. The firm has a market cap of $5.80 billion, a PE ratio of 60.37 and a beta of 1.25. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $35.02. The stock’s 50 day simple moving average is $26.37 and its two-hundred day simple moving average is $21.49.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.04) earnings per share. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of HIMS. Quest Partners LLC grew its holdings in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp acquired a new stake in Hims & Hers Health in the 2nd quarter valued at $111,000. CWM LLC increased its holdings in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Quarry LP raised its position in Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after acquiring an additional 2,913 shares during the period. Finally, Amalgamated Bank lifted its holdings in Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the topic of several research analyst reports. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Finally, TD Cowen reissued a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $22.80.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.